Long noncoding RNAs in renal diseases

Liu, Minghui; Ren, Jie

doi:10.1186/s41544-019-0033-x

Cited by 3 publications

(3 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… "Long noncoding RNAs in renal diseases" published in ExRNA. This review summarizes available studies indicating that lncRNAs are heavily involved in kidney development and disease and proposes lncRNAs as novel biomarkers for clinical diagnosis and potential therapeutic targets in renal diseases [19].  "Non-Coding RNA and Renal Disease" published in Frontiers Research Topic.…”

Section: Related Workmentioning

confidence: 99%

Long Non-Coding RNAs in Kidney Injury: A Comprehensive Review

Bhat,

Shanbhag

2024

JPDMHD

View full text Add to dashboard Cite

Kidney injury, a global health challenge, necessitates a nuanced understanding of molecular intricacies for effective interventions. Long non-coding RNAs (lncRNAs), once dismissed as transcriptional noise, now emerge as pivotal players in orchestrating renal health. Dysregulation of specific lncRNAs like TUG1, MALAT1, H19, and NEAT1 provides molecular signatures, distinguishing physiological states from pathological conditions. In acute kidney injury (AKI), TUG1 and MALAT1 regulate apoptosis, inflammation, and fibrosis. Chronic kidney disease (CKD) involves lncRNAs like H19 and NEAT1 modulating cell proliferation and apoptosis. Beyond diagnostics, lncRNAs actively shape inflammation, apoptosis, and fibrosis, positioning them as master regulators in the intricate ballet of kidney health. Recent strides in research, coupled with cutting-edge genomics and bioinformatics tools, highlight their roles and therapeutic potential. Challenges in understanding their intricate roles and interactions necessitate the exploration of promising avenues, including single-cell RNA sequencing and artificial intelligence, paving the way for personalized interventions and regenerative medicine in kidney diseases.

show abstract

Section: Related Workmentioning

confidence: 99%

Long Non-Coding RNAs in Kidney Injury: A Comprehensive Review

Bhat,

Shanbhag

2024

JPDMHD

View full text Add to dashboard Cite

show abstract

“…These investigations have identified gene expression profiles and determined how they differ during health and disease. Many transcriptomic studies investigating kidney disease have focused on examining messenger RNA (mRNA) or the ncRNA subtype, micro RNA (miRNA) (23); however, attention has turned to the contributions made by other ncRNAs such as, ribosomal RNA (rRNA), transfer RNA (tRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA) or long non-coding RNA (lncRNA), with this area of research undergoing recent reviews (141)(142)(143). Potential exists to harness RNAs as novel biomarkers for kidney disease pathogenesis or progression, with a distinct focus on urinary RNAs, particularly those contained with extracellular vesicles (protective membrane bound carriers released by cells), as a less invasive and robust means of disease diagnosis (144)(145)(146)(147)(148).…”

Section: Emerging Insights From Transcriptomic Analysis Of Ckdmentioning

confidence: 99%

Harnessing the Full Potential of Multi-Omic Analyses to Advance the Study and Treatment of Chronic Kidney Disease

Hill¹,

Ávila-Palència²,

Maxwell³

et al. 2022

Front. Nephrol.

View full text Add to dashboard Cite

Chronic kidney disease (CKD) was the 12th leading cause of death globally in 2017 with the prevalence of CKD estimated at ~9%. Early detection and intervention for CKD may improve patient outcomes, but standard testing approaches even in developed countries do not facilitate identification of patients at high risk of developing CKD, nor those progressing to end-stage kidney disease (ESKD). Recent advances in CKD research are moving towards a more personalised approach for CKD. Heritability for CKD ranges from 30% to 75%, yet identified genetic risk factors account for only a small proportion of the inherited contribution to CKD. More in depth analysis of genomic sequencing data in large cohorts is revealing new genetic risk factors for common diagnoses of CKD and providing novel diagnoses for rare forms of CKD. Multi-omic approaches are now being harnessed to improve our understanding of CKD and explain some of the so-called ‘missing heritability’. The most common omic analyses employed for CKD are genomics, epigenomics, transcriptomics, metabolomics, proteomics and phenomics. While each of these omics have been reviewed individually, considering integrated multi-omic analysis offers considerable scope to improve our understanding and treatment of CKD. This narrative review summarises current understanding of multi-omic research alongside recent experimental and analytical approaches, discusses current challenges and future perspectives, and offers new insights for CKD.

show abstract

“…It is expressed from the HOXC locus and repress the transcription from distant HOXD cluster by recruiting PRC2 [ 62 ]. Moreover, whether in a cis or trans way, lncRNAs bring out their gene regulatory activities either as signal lncRNAs, guide lncRNAs, decoy lncRNAs, or scaffold lncRNAs [ 63 ].…”

Section: Lncrnas: Classification and Biogenesismentioning

confidence: 99%

The Role of Long Non-Coding RNAs (lncRNAs) in Female Oriented Cancers

Naz

Tariq

Ali

et al. 2021

Cancers

View full text Add to dashboard Cite

Recent advances in molecular biology have discovered the mysterious role of long non-coding RNAs (lncRNAs) as potential biomarkers for cancer diagnosis and targets for advanced cancer therapy. Studies have shown that lncRNAs take part in the incidence and development of cancers in humans. However, previously they were considered as mere RNA noise or transcription byproducts lacking any biological function. In this article, we present a summary of the progress on ascertaining the biological functions of five lncRNAs (HOTAIR, NEAT1, H19, MALAT1, and MEG3) in female-oriented cancers, including breast and gynecological cancers, with the perspective of carcinogenesis, cancer proliferation, and metastasis. We provide the current state of knowledge from the past five years of the literature to discuss the clinical importance of such lncRNAs as therapeutic targets or early diagnostic biomarkers. We reviewed the consequences, either oncogenic or tumor-suppressing features, of their aberrant expression in female-oriented cancers. We tried to explain the established mechanism by which they regulate cancer proliferation and metastasis by competing with miRNAs and other mechanisms involved via regulating genes and signaling pathways. In addition, we revealed the association between stated lncRNAs and chemo-resistance or radio-resistance and their potential clinical applications and future perspectives.

show abstract

Long noncoding RNAs in renal diseases

Cited by 3 publications

References 94 publications

Long Non-Coding RNAs in Kidney Injury: A Comprehensive Review

Long Non-Coding RNAs in Kidney Injury: A Comprehensive Review

Harnessing the Full Potential of Multi-Omic Analyses to Advance the Study and Treatment of Chronic Kidney Disease

The Role of Long Non-Coding RNAs (lncRNAs) in Female Oriented Cancers

Contact Info

Product

Resources

About